Allergy Therapeutics Share Discussion Threads

[goodman] 28/3/2014 16:43

Well somebody likes them, 800K & 500k buys at the end.

[doodlebug4] 28/3/2014 16:28

barefoot - good posts, I agree.

[jimmyloser] 28/3/2014 16:24

Will we get Cube's wish and see Directors buys?

[barefoot141] 28/3/2014 12:28

By the way if it drops below 20p i will take a sharp intake of breath and top up. Did the same with TCG, FLYB, THT and others on recent pullbacks on their road to recovery. All about your own personal trading/investing strategy.

[barefoot141] 28/3/2014 12:24

Malcolm. If we didn't have different opinions, view and tolerance levels then there would be no buys or sells and a boring world. If it drops it drops if it rises it rises. As long as you are comfortable with the choices you make then happy days. GLA

[barefoot141] 28/3/2014 12:19

No change with me. Think the story is strong and recovery well underway. The biotech sector like tech stocks has taken a bashing in the US over the last week so a bit of a knock on effect. Still like the chart and the company and happy to be patient. Couple of dents Jimmy in the ole tin hat but 'war is hell'

[malcolmdgama04] 28/3/2014 12:17

Well done druinsky.. better late than never

[druinsky] 28/3/2014 11:44

thank i sold

[cube boss] 28/3/2014 11:43

This is a decent BB, it would be nice to keep it that way! Good luck Malcolm with any new venture, will be happy to see you back when you think the time is right for you...:0)) GLA

[malcolmdgama04] 28/3/2014 10:58

i have never posted other shares on here other than today.

i thought it might be helpful.

[audigger] 28/3/2014 10:01

About to go blue......!

[jimmyloser] 28/3/2014 09:46

malcolm
I am sorry that you show your annoyance in such a way
I was naffed ouff with you posting other shares on this forum

This is AGY

You can say whatever you feel about AGY - x

[malcolmdgama04] 28/3/2014 09:44

yes i agree.. Its a good share . I will get in again.. i think once its carmed down a litle.

[lufcscott] 28/3/2014 09:38

Calm down all will come good. Don't look day to day look long term . It's a marathon not a sprint

[cube boss] 28/3/2014 09:30

Your showing your true colours Malcolm.:0)

[malcolmdgama04] 28/3/2014 09:18

and down we go..

[malcolmdgama04] 28/3/2014 09:09

We should see another 10% drop today.. already 4.5% down now..

[malcolmdgama04] 28/3/2014 09:02

we are just on the edge of tumbling.. and will be worth topping up at 16p..

[malcolmdgama04] 28/3/2014 08:59

Is it becuase we've hit 21p and may fall to 18p and below??

[malcolmdgama04] 28/3/2014 08:48

I'm sorry jimmy.. But whats with the attitude.. a bit cranky today.

[jimmyloser] 28/3/2014 08:36

Malcolm
PI*S OFF

[malcolmdgama04] 28/3/2014 08:26

Hi guys.

Have a look at RMM. It might be worth a buy.

[jimmyloser] 28/3/2014 07:44

Morning Cube,
Tin hat day again today? - stay cool. The fundamentals and prospects are solid.

Look before you leap! would be worth people considering.

I read the following as an indirect reference to Tim and his work.

I personally do not want any director buying. If they did, it says that they are much further away from an American deal that I believe they are.



We are also pleased to report progress from within R&D where we initiated a phase II clinical study for Pollinex Quattro in Europe under the TAV regulatory framework. The primary objective of this dose finding study is to compare the difference between four individual Pollinex Quattro Birch dose regimens (600SU, 1550SU, 5100SU and 13600SU (cumulative doses)) with respect to the change seen from baseline to post-treatment in Total Symptom Score ("TSS") recorded following a Conjunctival Provocation Test. This multi-centre phase II study uses a 1:1:1:1 randomisation and parallel-group, double-blind design to evaluate the efficacy and safety/tolerability of Pollinex Quattro Birch in subjects with seasonal allergic rhinoconjunctivitis. The study is being conducted in Germany, Austria and Poland prior to the birch pollen season. Recruitment began in September 2013 and 140 subjects were enrolled with 35 subjects per treatment arm. The last patient completed the trial on 31 January 2014.

Finally, our Executive Team welcomes Professor Tim Higenbottam as the Company's new R&D Director.

[goodman] 27/3/2014 18:51

Well with 30 trades going through today only five were buys, the 25 sells were tiny,the largest was just 25100.total buys were 15500 against 25 sells of 306000.
So it's just people taking there small profits, I will keep mine and may well add more if it goes down further but will out at 15p for a no loss adventure.